|
The Virginia Biosciences Health Research Corporation, known as Virginia Catalyst, today announced that it has awarded a $400,000 grant to a collaborative bioscience commercialization project including a team from Virginia Commonwealth University, Eastern Virginia Medical School and ReAlta Life Sciences, LLC. This grant, which includes matching funding of $400,000 provided by ReAlta, is intended to establish the efficacy of Peptide Inhibitor of Complement C1 (PIC1) in decreasing brain injury in an animal model of neonatal Hypoxic-Ischemic Encephalopathy (HIE), as well as establish the long-term improvement in neurological outcomes after PIC1 treatment in an animal model of neonatal HIE.
Read the full press release here.
0 Comments
|
RSS Feed
